Evercore ISI Starts Entrada Therapeutics (TRDA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TRDA Hot Sheet
Price: $5.06 +7.20%
Rating Summary:
6 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
6 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Evercore ISI analyst Jonathan Miller initiates coverage on Entrada Therapeutics (NASDAQ: TRDA) with a Outperform rating.
For an analyst ratings summary and ratings history on Entrada Therapeutics click here. For more ratings news on Entrada Therapeutics click here.
Shares of Entrada Therapeutics closed at $24.23 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Cantor Fitzgerald Starts Netskope (NTSK) at Overweight
- Canaccord Starts Carrier Connect Data Solutions (CCDS:CN) at Spec. Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
